| 0.65 0 (0%) | 06-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.77 | 1-year : | 0.8 |
| Resists | First : | 0.65 | Second : | 0.68 |
| Pivot price | 0.65  |
|||
| Supports | First : | 0.61 | Second : | 0.5 |
| MAs | MA(5) : | 0.63  |
MA(20) : | 0.65 |
| MA(100) : | 0.62 |
MA(250) : | 0.58 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 43.8 |
D(3) : | 36.2 |
| RSI | RSI(14): 48.2 | |||
| 52-week | High : | 1.96 | Low : | 0.28 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VYNE ] has closed above bottom band by 47.0%. Bollinger Bands are 28.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.66 - 0.66 | 0.66 - 0.66 |
| Low: | 0.64 - 0.64 | 0.64 - 0.64 |
| Close: | 0.64 - 0.65 | 0.65 - 0.66 |
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.
Fri, 19 Jun 2026
Vyne Therapeutics Inc (VYNE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fri, 19 Jun 2026
Vyne Therapeutics Inc (VYNE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Wed, 17 Jun 2026
Vyne Therapeutics Inc (VYNE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Wed, 17 Jun 2026
[EFFECT] VYNE Therapeutics Inc. SEC Filing - Stock Titan
Mon, 15 Jun 2026
Zhang Xiaofan discloses 1.87M shares (5.6%) in VYNE Therapeutics (VYNE) - Stock Titan
Tue, 02 Jun 2026
[Form 4] VYNE Therapeutics Inc. Insider Trading Activity - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 3.255e+007 (%) |
| Held by Institutions | 4.5 (%) |
| Shares Short | 121 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.434e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 437.2 % |
| Return on Equity (ttm) | -37.1 % |
| Qtrly Rev. Growth | 454000 % |
| Gross Profit (p.s.) | 27.39 |
| Sales Per Share | -33.48 |
| EBITDA (p.s.) | 285000 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 120420 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|